Payment overview · 2025
General Payments
$1,654.11
59 reported records · 24 companies
Healthcare provider profile · identity verified
Aymen Atallah, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BOYNTON BEACH, FL · NPI 1417902339
Verified facts
What the public records show
CMS Open Payments records show Aymen Atallah, MD received $1,654.11 in general payments during 2025 across 59 reported records.
AstraZeneca Pharmaceuticals LP accounted for 16.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 152 claims for Farxiga by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 1034 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 77 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 158 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1034 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $277.74 | 16.8% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $209.71 | 12.7% | 6 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $128.52 | 7.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $120.14 | 7.3% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $116.61 | 7.0% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $105.39 | 6.4% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $89.69 | 5.4% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $88.65 | 5.4% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $76.53 | 4.6% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $54.94 | 3.3% | 2 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$54.73 | 3.3% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $53.64 | 3.2% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $41.19 | 2.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.32 | 1.9% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $31.03 | 1.9% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $25.05 | 1.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.42 | 1.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $21.77 | 1.3% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $21.19 | 1.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.83 | 1.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.47 | 1.1% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.97 | 1.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.74 | 0.9% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $13.84 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,609.11 | 58 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $277.74 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $194.04 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $180.79 | 4 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $128.52 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $116.61 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $76.53 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $59.46 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $58.94 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $58.17 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $58.17 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $54.94 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $47.47 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $41.19 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.32 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.32 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $31.03 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.23 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $25.05 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.42 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $21.77 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $21.19 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.83 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.47 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $16.97 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.74 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $14.74 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $13.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1034 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 152 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 77 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 101 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 60 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
92 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
152 | 27 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1034 | 132 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
41 | 41 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
16 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
60 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
77 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
56 | 11 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
158 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
101 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1034 | 132 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1536 | 330 |
| Eliquis | Apixaban | 1034 | 132 |
| Levothyroxine Sodium | Levothyroxine Sodium | 955 | 197 |
| Amlodipine Besylate | Amlodipine Besylate | 947 | 236 |
| Gabapentin | Gabapentin | 702 | 146 |
| Tamsulosin Hcl | Tamsulosin Hcl | 676 | 141 |
| Pantoprazole Sodium | Pantoprazole Sodium | 672 | 154 |
| Furosemide | Furosemide | 657 | 158 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 652 | 194 |
| Metoprolol Succinate | Metoprolol Succinate | 603 | 141 |
| Trazodone Hcl | Trazodone Hcl | 583 | 127 |
| Losartan Potassium | Losartan Potassium | 560 | 132 |
| Famotidine | Famotidine | 517 | 120 |
| Metformin Hcl | Metformin Hcl | 499 | 129 |
| Donepezil Hcl | Donepezil Hcl | 414 | 76 |
| Xarelto | Rivaroxaban | 414 | 51 |
| Lisinopril | Lisinopril | 410 | 104 |
| Potassium Chloride | Potassium Chloride | 387 | 91 |
| Metoprolol Tartrate | Metoprolol Tartrate | 369 | 92 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 345 | 108 |
| Escitalopram Oxalate | Escitalopram Oxalate | 344 | 76 |
| Carvedilol | Carvedilol | 342 | 72 |
| Clopidogrel | Clopidogrel Bisulfate | 332 | 73 |
| Hydralazine Hcl | Hydralazine Hcl | 320 | 82 |
| Sertraline Hcl | Sertraline Hcl | 316 | 67 |
| Mirtazapine | Mirtazapine | 308 | 67 |
| Omeprazole | Omeprazole | 296 | 85 |
| Memantine Hcl | Memantine Hcl | 261 | 53 |
| Ezetimibe | Ezetimibe | 251 | 74 |
| Duloxetine Hcl | Duloxetine Hcl | 238 | 58 |
| Finasteride | Finasteride | 236 | 52 |
| Levetiracetam | Levetiracetam | 228 | 40 |
| Valsartan | Valsartan | 208 | 59 |
| Hydrochlorothiazide | Hydrochlorothiazide | 202 | 54 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 195 | 31 |
| Alprazolam | Alprazolam | 186 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 183 | 40 |
| Allopurinol | Allopurinol | 180 | 45 |
| Simvastatin | Simvastatin | 175 | 40 |
| Latanoprost | Latanoprost | 174 | 35 |
| Quetiapine Fumarate | Quetiapine Fumarate | 173 | 52 |
| Midodrine Hcl | Midodrine Hcl | 166 | 40 |
| Spironolactone | Spironolactone | 166 | 48 |
| Januvia | Sitagliptin Phosphate | 162 | 28 |
| Entresto | Sacubitril/Valsartan | 158 | 27 |
| Divalproex Sodium | Divalproex Sodium | 157 | 36 |
| Farxiga | Dapagliflozin Propanediol | 152 | 27 |
| Buspirone Hcl | Buspirone Hcl | 151 | 30 |
| Montelukast Sodium | Montelukast Sodium | 151 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 145 | 32 |
| Nifedipine Er | Nifedipine | 142 | 30 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 133 | 74 |
| Ondansetron Hcl | Ondansetron Hcl | 131 | 64 |
| Bumetanide | Bumetanide | 125 | 33 |
| Nystatin | Nystatin | 117 | 55 |
| Prednisone | Prednisone | 117 | 40 |
| Amiodarone Hcl | Amiodarone Hcl | 111 | 27 |
| Sucralfate | Sucralfate | 111 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 103 | 19 |
| Paroxetine Hcl | Paroxetine Hcl | 102 | 25 |
| Permethrin | Permethrin | 102 | 55 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 101 | 26 |
| Ozempic | Semaglutide | 101 | 22 |
| Atenolol | Atenolol | 99 | 22 |
| Baclofen | Baclofen | 93 | 20 |
| Synthroid | Levothyroxine Sodium | 92 | 24 |
| Temazepam | Temazepam | 91 | 17 |
| Alendronate Sodium | Alendronate Sodium | 88 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 86 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 86 | 59 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 81 | 63 |
| Jardiance | Empagliflozin | 77 | 21 |
| Aripiprazole | Aripiprazole | 76 | 20 |
| Methylprednisolone | Methylprednisolone | 76 | 58 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 75 | 32 |
| Myrbetriq | Mirabegron | 73 | 17 |
| Sodium Chloride | 0.9 % Sodium Chloride | 73 | 44 |
| Fenofibrate | Fenofibrate | 72 | 16 |
| Ivermectin | Ivermectin | 72 | 35 |
| Zolpidem Tartrate | Zolpidem Tartrate | 72 | 14 |
| Primidone | Primidone | 70 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 69 | 25 |
| Dutasteride | Dutasteride | 68 | 17 |
| Mupirocin | Mupirocin | 68 | 46 |
| Risperidone | Risperidone | 68 | 21 |
| Oxybutynin Chloride | Oxybutynin Chloride | 66 | 14 |
| Azithromycin | Azithromycin | 65 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 26 |
| Tramadol Hcl | Tramadol Hcl | 63 | 27 |
| Metformin Hcl Er | Metformin Hcl | 61 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | 14 |
| Methenamine Hippurate | Methenamine Hippurate | 59 | 13 |
| Olanzapine | Olanzapine | 59 | 15 |
| Dorzolamide Hcl | Dorzolamide Hcl | 58 | 11 |
| Warfarin Sodium | Warfarin Sodium | 58 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 57 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 57 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 57 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 56 | 16 |
| Nuplazid | Pimavanserin Tartrate | 56 | suppressed |
| Trulicity | Dulaglutide | 56 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 55 | 18 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 55 | 20 |
| Clonazepam | Clonazepam | 54 | 11 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 54 | 16 |
| Levofloxacin | Levofloxacin | 54 | 38 |
| Propranolol Hcl | Propranolol Hcl | 54 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 53 | 22 |
| Movantik | Naloxegol Oxalate | 53 | suppressed |
| Bupropion Xl | Bupropion Hcl | 51 | 13 |
| Clonidine Hcl | Clonidine Hcl | 51 | 18 |
| Celecoxib | Celecoxib | 50 | 18 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 50 | 15 |
| Timolol Maleate | Timolol Maleate | 50 | 12 |
| Budesonide | Budesonide | 49 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 49 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 49 | 34 |
| Breo Ellipta | Fluticasone/Vilanterol | 47 | 12 |
| Hydrocortisone | Hydrocortisone | 47 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 46 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 46 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 46 | 16 |
| Incruse Ellipta | Umeclidinium Bromide | 46 | suppressed |
| Insulin Lispro | Insulin Lispro | 46 | 17 |
| Lactulose | Lactulose | 46 | 13 |
| Meloxicam | Meloxicam | 45 | 18 |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 45 | 12 |
| Digoxin | Digoxin | 43 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 43 | 12 |
| Ertapenem | Ertapenem Sodium | 43 | 18 |
| Letrozole | Letrozole | 43 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 43 | 15 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 41 | 41 |
| Glimepiride | Glimepiride | 41 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 34 |
| Cefuroxime | Cefuroxime Axetil | 40 | 26 |
| Enalapril Maleate | Enalapril Maleate | 40 | suppressed |
| Linzess | Linaclotide | 40 | suppressed |
| Novolog Flexpen | Insulin Aspart | 40 | 12 |
| Telmisartan | Telmisartan | 40 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 39 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 39 | 15 |
| Novolog | Insulin Aspart | 38 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 29 |
| Tizanidine Hcl | Tizanidine Hcl | 38 | 21 |
| Mounjaro | Tirzepatide | 36 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | suppressed |
| Ranolazine Er | Ranolazine | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | suppressed |
| Ketoconazole | Ketoconazole | 35 | 23 |
| Tradjenta | Linagliptin | 35 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 35 | suppressed |
| Brilinta | Ticagrelor | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 34 | 13 |
| Rybelsus | Semaglutide | 34 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 33 | 18 |
| Brimonidine Tartrate | Brimonidine Tartrate | 33 | suppressed |
| Glatiramer Acetate | Glatiramer Acetate | 33 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 32 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 32 | 22 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 32 | suppressed |
| Torsemide | Torsemide | 32 | suppressed |
| Diazepam | Diazepam | 31 | suppressed |
| Humalog | Insulin Lispro | 31 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 12 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 30 | suppressed |
| Folic Acid | Folic Acid | 30 | suppressed |
| Methimazole | Methimazole | 30 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 29 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 29 | suppressed |
| Glucagon Emergency Kit | Glucagon | 29 | 21 |
| Insulin Aspart Flexpen | Insulin Aspart | 29 | 11 |
| Memantine Hcl Er | Memantine Hcl | 29 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 29 | suppressed |
| Repatha Sureclick | Evolocumab | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | 11 |
| Glipizide | Glipizide | 28 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Lamotrigine | Lamotrigine | 27 | suppressed |
| Felodipine Er | Felodipine | 26 | suppressed |
| Methotrexate | Methotrexate Sodium | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | 12 |
| Labetalol Hcl | Labetalol Hcl | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Bicalutamide | Bicalutamide | 24 | suppressed |
| Clotrimazole | Clotrimazole | 24 | suppressed |
| Ssd | Silver Sulfadiazine | 24 | suppressed |
| Amoxicillin | Amoxicillin | 23 | 17 |
| Cephalexin | Cephalexin | 23 | 16 |
| Clonidine | Clonidine | 23 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 23 | 14 |
| Galantamine Hbr | Galantamine Hbr | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Meropenem | Meropenem | 23 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 23 | suppressed |
| Insulin Aspart | Insulin Aspart | 22 | suppressed |
| Lumigan | Bimatoprost | 22 | suppressed |
| Sotalol | Sotalol Hcl | 22 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 21 | 19 |
| Irbesartan | Irbesartan | 21 | suppressed |
| Novolin R | Insulin Regular, Human | 21 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 21 | suppressed |
| Creon | Lipase/Protease/Amylase | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 14 |
| Gentamicin Sulfate | Gentamicin Sulfate | 20 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 20 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Zosyn | Piperacillin-Tazo-Dextrose,iso | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 19 | suppressed |
| Anastrozole | Anastrozole | 18 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 18 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 18 | suppressed |
| Glipizide Er | Glipizide | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 18 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 17 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Cefdinir | Cefdinir | 17 | 12 |
| Mometasone Furoate | Mometasone Furoate | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Phenobarbital | Phenobarbital | 17 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Alogliptin | Alogliptin Benzoate | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | 14 |
| Prednisolone Acetate | Prednisolone Acetate | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | 15 |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Meropenem-0.9% Nacl | Meropenem-0.9% Sodium Chloride | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Mirabegron Er | Mirabegron | 15 | suppressed |
| Praluent Pen | Alirocumab | 15 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Ampicillin-Sulbactam | Ampicillin Sod/Sulbactam Sod | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 14 | suppressed |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 14 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Entacapone | Entacapone | 13 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Ramipril | Ramipril | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 12 | suppressed |
| Dexamethasone | Dexamethasone | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Estradiol | Estradiol | 12 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Hydroxyurea | Hydroxyurea | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Nystop | Nystatin | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Zafirlukast | Zafirlukast | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Insulin Lispro Junior Kwikpen | Insulin Lispro | 11 | suppressed |
| Mesalamine Er | Mesalamine | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 11 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 11 | suppressed |
| Verapamil Sr | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,654.11 · 59 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FANAPT, FARXIGA, FREESTYLE LIBRE 3, GARDASIL 9, INGREZZA, JARDIANCE, JATENZO, LEQVIO, Leqembi, MOUNJARO, ONPATTRO, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, WATCHMAN FLX, Wegovy, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error